Skip to content

Similar metrics at other companies

BlackSky Technology logo
BKSY2028
$0-100%
General Dynamics logo
GD2028
$169M-2.9%
BlackSky Technology logo
BKSY2029
$0-100%
Everspin Technologies logo
MRAM2028
$595K
General Dynamics logo
GD2027
$175M-1.7%
BlackSky Technology logo
BKSY2027
$0-100%

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.13B+17.9%
Enterprise value$845.67M-0.3%
P/E15.1×-6.8×
P/S1.4×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s jornay pm — 2028.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s jornay PM — 2028?
Collegium Pharmaceutical, Inc. (COLL) reported jornay PM — 2028 of $83.83M in Q1 2026.
How has Collegium Pharmaceutical, Inc.'s jornay PM — 2028 changed year-over-year?
Collegium Pharmaceutical, Inc.'s jornay PM — 2028 decreased by 0.0% year-over-year, from $83.83M to $83.83M.
What does jornay PM — 2028 mean?
This represents the projected financial impact or specific asset-related value associated with a product for the calendar year 2028. It provides visibility into the long-term amortization profile and expected asset utilization for the product.